M-A of randomized trials | Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors. 24 Aug, 2022 | 14:12h | UTC Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials – Cancer Medicine